| 摘要 |
<p>The invention provides proteins which are variants of human Leukemia Inhibitory Factor (hLIF) with altered binding affinities to the LIF receptor and to the gp130 receptor. Such proteins include hLIF which has been altered by substitution at, insertion into, or deletion within a portion of said sequence such that the affinity for the LIF receptor is lowered compared to LIF, or a fragment of said protein which contains said alteration. Such proteins also include hLIF which has been altered by substitution at, insertion into, or deletion within a portion of said sequence such that the affinity for the gp130 receptor is lowered compared to LIF, or a fragment of said protein which contains said alteration.</p> |
